FDA and DEA call on AD­HD drug man­u­fac­tur­ers to up pro­duc­tion amid on­go­ing short­ages

The US FDA and Drug En­force­ment Ad­min­is­tra­tion sent a joint let­ter Tues­day to the pub­lic say­ing that they’re work­ing over­time try­ing to wran­gle short­ages of Adder­all and oth­er stim­u­lant med­ica­tions used to treat AD­HD.

While the FDA and DEA can­not force man­u­fac­tur­ers to in­crease their sup­plies, the two agen­cies said that last year, man­u­fac­tur­ers of am­phet­a­mines like Adder­all did not hit their quo­tas for how much they can legal­ly pro­duce.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER